- AMW grants license to undisclosed partner for commercialization of its goserelin implant in a LATAM country
- Strengthening of availability of goserelin for patients suffering from prostate and breast cancer, as well as other indications as per approved label.
- Goserelin licensed now in > 50 countries
AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announces that it has entered into a license and supply agreement (LSA) with an undisclosed partner for the commercialization of its goserelin implant in a relevant LATAM country. AMW’s new LATAM partner is active and highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients.
Under the terms of this agreement, the partner will distribute goserelin in its territory. AMW will receive license payments and will exclusively manufacture and supply goserelin under pre-agreed terms based on minimum annual quantities (MAQ).
To date, AMW, has licensed goserelin to global and local pharma leaders in more than 50 countries.
Konstantin Petropoulos, CEO of AMW GmbH commented: “We are pleased to add another great partner for our goserelin product. Expanding our global goserelin product reach enables superior and/or cost-efficient treatment solutions for more patients across a growing number of countries. As a market leader for biodegradable slow-release drug delivery systems, we will continue to expand the opportunity of making goserelin available for patients across the globe.”
For more information, please contact:
Dr. Konstantin Petropoulos +49 8024 470999-0
AMW GmbH is a specialty pharmaceutical company focused on innovative drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four products on the market (goserelin & leuprorelin implants, rivastigmin & buprenorphine patches).
AMW is based in Warngau, south of Munich.
Goserelin contains the active ingredient goserelin and belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormonesensitive tumors such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.